ReviewAnnals of hematology2021
Hematologic disorders associated with COVID-19: a review.
Review in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 104 citations in OpenAlex.
- Platelet-to-Lymphocyte Ratio-A Real or Fake Bridge Between Inflammation and Coagulation in COVID-19 Patients: A Scoping Review.Diagnostics (Basel, Switzerland) · 2026Review
- COVID-19-induced thrombotic microangiopathy in patients with multiple myeloma receiving carfilzomib treatment.International journal of hematology · 2025Article
- SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.Microorganisms · 2025Review
- Hematological Markers in Thromboembolic Events: A Comparative Study of COVID-19 and Non-COVID-19 Hospitalized Patients.Journal of clinical medicine · 2025Article
- Dynamic changes in platelet counts and psychological state in ITP patients after COVID-19 infection.Frontiers in medicine · 2025Article
- Integrating ensemble and machine learning models for early prediction of pneumonia mortality using laboratory tests.Heliyon · 2024Article
- COVID-19 was associated with the complications after allogeneic hematopoietic stem cell transplantation.Scientific reports · 2024Article
- 3D Holo-tomographic Mapping of COVID-19 Microclots in Blood to Assess Disease Severity.Chemical & biomedical imaging · 2024Article
- Laboratory Diagnostics Accuracy for COVID-19 versus Post-COVID-19 Syndrome in Lung Disease Patients with Multimorbidity.Journal of personalized medicine · 2024Article
- Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes.Journal of clinical medicine research · 2024Article
- Modulation in serum and hematological parameters as a prognostic indicator of COVID-19 infection in hypertension, diabetes mellitus, and different cardiovascular diseases.Frontiers in chemistry · 2024Article
- The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients.Advances in hematology · 2024Article
- Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit.Journal of thoracic disease · 2023Article
- Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities.Current issues in molecular biology · 2023Review
- Assessing the Impact of COVID-19 Vaccines on Sickle Cell Anaemia Patients: A Comparative Analysis of Biochemical and Haematological Parameters.Biomedicines · 2023Article
- COVID-19 infection: a possible induction factor for development of autoimmune diseases?Immunologic research · 2023Review
- Role of Therapeutic Anticoagulation in COVID-19: The Current Situation.Hematology reports · 2023Review
- Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement.Annals of hematology · 2023Review
- Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation.International journal of molecular sciences · 2023Review
- Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group.Infectious diseases and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2. Primarily an infection of the lower respiratory tract, it is now well known to cause multisystem abnormalities. Hematologic manifestations constitute a significant area of concern. Severe acute respiratory syndrome coronavirus 2 infects monocytes and endothelial cells leading to a complex downstream cascade, cytokine storm, and eventual intravascular thrombosis. Coronavirus disease 2019 causes lymphopenia, neutrophilia, and thrombocytopenia. Prophylactic anticoagulation is vital in patients with coronavirus disease 2019, as its effect on the coagulation system is associated with significant morbidity and mortality. The disease can cause both arterial and venous thromboses, especially pulmonary embolism and pulmonary microthrombi. A high index of suspicion is indispensable in recognizing these complications, and timely institution of therapeutic anticoagulation is vital in treating them. Virus-induced disseminated intravascular coagulation is uncommon but shares some similarities to sepsis-induced disseminated intravascular coagulation. Marked elevations in hematologic biomarkers such as lactate dehydrogenase, D-dimer, ferritin, and C-reactive protein are associated with worse outcomes. Understanding the pathophysiology and recognizing factors associated with poor prognosis are crucial in improving patient outcomes with coronavirus disease 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.